Sangamo Therapeutics Inc (LTS:0R1D)
$ 2.18 -0.06 (-2.68%) Market Cap: 492.41 Mil Enterprise Value: 480.93 Mil PE Ratio: 0 PB Ratio: 12.55 GF Score: 41/100

Sangamo Therapeutics Inc at Barclays Gene Editing & Gene Therapy Summit (Virtual) Transcript

Nov 15, 2021 / 03:30PM GMT
Release Date Price: $9.89 (-2.37%)
Huidong Wang
Barclays Bank PLC, Research Division - Research Analyst

Good morning, everyone. My name is Gena Wang. I'm SMID cap biotech analyst at Barclays. Welcome to our fifth Gene Editing and Gene Therapy Summit. It is my great pleasure to introduce our next speaker, Sandy Macrae, President and Chief Executive Officer from Sangamo Therapeutics. Sandy, I hand over to you for introduction.

Alexander D. Macrae
Sangamo Therapeutics, Inc. - CEO, President & Director

Good morning, Gena. It's always a pleasure to be here with you. And thank you to the team for putting together and running these slides for me. So can we go to the next slide, please. As always, we guide you to our forward-looking statements.

Next slide, please. And I want to describe a genomic medicine company. I want to describe Sangamo and its unique and novel science that we have driven forward and delivered on clinical stage programs. And underpinning that, we have our own manufacturing that allows us to be in control of our product and our fate.

Next slide, please. And

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot